Stockscreener 앱 받기
4.56
5.00%
-0.24
시간 외 거래:
4.58
0.02
+0.44%
전일 마감가:
$4.80
열려 있는:
$4.79
하루 거래량:
3.30M
Relative Volume:
0.75
시가총액:
$1.61B
수익:
$6.23M
순이익/손실:
$-95.90M
주가수익비율:
-11.69
EPS:
-0.39
순현금흐름:
$-68.47M
1주 성능:
+2.24%
1개월 성능:
+6.54%
6개월 성능:
+159.09%
1년 성능:
+242.86%
1일 변동 폭
$4.45
$4.8996
1주일 범위
$4.30
$5.02
52주 변동 폭
$1.11
$5.225
Precigen Inc Stock (PGEN) Company Profile
명칭
Precigen Inc
전화
301-556-9900
주소
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
PGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
4.56 | 1.70B | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.52 | 118.13B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
775.06 | 79.79B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
850.87 | 52.71B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
351.96 | 46.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
352.00 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-15 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-03-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-05-23 | 개시 | JP Morgan | Neutral |
| 2022-11-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-25 | 개시 | Stifel | Buy |
| 2021-02-22 | 개시 | Wells Fargo | Overweight |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-05-08 | 개시 | H.C. Wainwright | Buy |
모두보기
Precigen Inc 주식(PGEN)의 최신 뉴스
Market Trends: Is Precigen Inc stock risky to hold nowTrade Ideas & Community Shared Stock Ideas - baoquankhu1.vn
Precigen (PGEN) Is Down 5.7% After Consensus Backs PAPZIMEOS As New First-Line RRP Therapy - simplywall.st
AI Stocks: Can Bioceres Crop Solutions Corp outperform under higher oil pricesMarket Trend Summary & Safe Capital Growth Stock Tips - baoquankhu1.vn
Precigen, Inc. (PGEN) Stock Analysis: 87% Upside Potential Ignites Investor Interest - DirectorsTalk Interviews
Institutional Investors May Overlook Precigen, Inc.'s (NASDAQ:PGEN) Recent US$110m Market Cap Drop as Long-term Gains Remain Positive - 富途牛牛
Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th - Nasdaq
Zacks Research Downgrades Precigen (NASDAQ:PGEN) to Strong Sell - MarketBeat
Precigen, Inc. (PGEN) Stock Analysis: Exploring a Potential 75% Upside in the Biotech Sector - DirectorsTalk Interviews
Market Pulse: Is Precigen Inc stock influenced by commodity pricesJuly 2025 Setups & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Why Precigen (PGEN) Is Up 5.3% After PAPZIMEOS Becomes First-Line RRP Standard of Care – And What's Next - simplywall.st
Patient Capital Management LLC Grows Stake in Precigen, Inc. $PGEN - MarketBeat
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis - Finviz
3 Growth Companies With High Insider Ownership And Up To 79% Earnings Growth - simplywall.st
Precigen, Inc. (NASDAQ:PGEN) Sees Large Growth in Short Interest - MarketBeat
Earnings Risk: Is Precigen Inc stock influenced by commodity prices2025 Price Targets & Low Volatility Stock Recommendations - baoquankhu1.vn
Precigen (NASDAQ:PGEN) Shares Gap UpWhat's Next? - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Assessing Precigen (PGEN) Valuation After PAPZIMEOS Commercial Momentum And EMA Milestone - Sahm
Is PGEN’s PAPZIMEOS Exclusivity Quietly Redefining Its Competitive Moat in Rare Disease Therapy? - simplywall.st
Precigen reports strong adoption of RRP treatment PAPZIMEOS By Investing.com - Investing.com Nigeria
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Precigen (NASDAQ:PGEN) Trading Down 7.5%What's Next? - MarketBeat
Precigen reports strong adoption of RRP treatment PAPZIMEOS - Investing.com
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Iridian Asset Management LLC CT Sells 611,716 Shares of Precigen, Inc. $PGEN - MarketBeat
New RRP treatment spreads nationwide as more insurers agree to cover it - Stock Titan
Is Precigen Inc. stock a buy on dipsInsider Buying & Technical Analysis for Trade Confirmation - ulpravda.ru
Precigen, Inc. (PGEN) Stock Analysis: Biotechnology Innovator With Potential 84% Upside - DirectorsTalk Interviews
Can Precigen Inc. stock beat market expectations this quarterJuly 2025 Review & Fast Moving Stock Trade Plans - ulpravda.ru
Can Precigen Inc. stock double in next 5 yearsMarket Weekly Review & Fast Exit and Entry Strategy Plans - ulpravda.ru
Precigen, Inc. (NASDAQ:PGEN): Are Analysts Optimistic? - simplywall.st
Market Sentiment Around Loss-Making Precigen, Inc. (NASDAQ:PGEN) - 富途牛牛
Is Precigen Inc. stock a buy before product launchesMorning Star Patterns & Start Small. End Wealthy. - ulpravda.ru
Will Precigen Inc. stock recover faster than peersGeopolitical Risk Analysis & Amplify Gains With Picks - ulpravda.ru
Will Precigen Inc. stock see insider buying2026 world cup usa national team quarterfinals star players possession football tactical prediction insights - ulpravda.ru
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Co - GuruFocus
Precigen (NASDAQ:PGEN) Trading Down 6.1%What's Next? - MarketBeat
Precigen (NASDAQ:PGEN) Trading Down 4.2%Here's What Happened - MarketBeat
Will PGEN’s New Drug Make a Splash? - StocksToTrade
Precigen (NASDAQ:PGEN) Shares Up 5.1%What's Next? - MarketBeat
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday - Benzinga
Precigen (NASDAQ:PGEN) Shares Gap Down Following Insider Selling - MarketBeat
Monday’s Insider Activity: Andreessen Horowitz Leads Major Buys - Investing.com
Monday’s Insider Activity: Andreessen Horowitz Leads Major Buys By Investing.com - Investing.com UK
Precigen Insider Sold Shares Worth $7,942,150, According to a Recent SEC Filing - marketscreener.com
Insider Selling: Precigen (NASDAQ:PGEN) Director Sells 1,900,036 Shares of Stock - MarketBeat
Kirk sells Precigen shares worth $7.9 million By Investing.com - Investing.com South Africa
Kirk sells Precigen shares worth $7.9 million - Investing.com
Precigen, Inc. (NASDAQ:PGEN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Precigen Inc (PGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.65%
3.42%
자본화:
|
볼륨(24시간):